Clinical Trial Update: Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial to evaluate the efficacy, safety, and tolerability of the anti-MTBR tau monoclonal antibody BMS-986446 in adults with Alzheimer's disease. The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• BMS-986446 (BMS-986446)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Alzheimer Disease, Early Onset | Phase 2 | Status: ACTIVE_NOT_RECRUITING